Eagle Historical Income Statement

EGRX Stock

USD 4.76 0.01 0.21%

Historical analysis of Eagle Pharmaceuticals income statement accounts such as Selling General Administrative of 118.5 M or Total Revenue of 382.3 M can show how well Eagle Pharmaceuticals performed in making a profits. Evaluating Eagle Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Eagle Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Eagle Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Eagle Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eagle Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.

About Eagle Income Statement Analysis

Eagle Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Eagle Pharmaceuticals shareholders. The income statement also shows Eagle investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Eagle Pharmaceuticals Income Statement Chart

Eagle Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Eagle's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Eagle Pharmaceuticals revenue and expense. Eagle Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.

At this time, Eagle Pharmaceuticals' Income Before Tax is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 9.6 M in 2024, whereas Research Development is likely to drop slightly above 32.8 M in 2024.

Total Revenue Gross Profit Other Operating Expenses Ebit

Total Revenue

Total revenue comprises all receipts Eagle Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Eagle Pharmaceuticals minus its cost of goods sold. It is profit before Eagle Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Eagle Pharmaceuticals. It is also known as Eagle Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most accounts from Eagle Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Eagle Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eagle Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.At this time, Eagle Pharmaceuticals' Income Before Tax is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 9.6 M in 2024, whereas Research Development is likely to drop slightly above 32.8 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	1.6M	4.0M	4.7M	4.9M
Depreciation And Amortization	3.8M	12.0M	13.8M	14.5M

Interest Expense Depreciation And Amortization

Eagle Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling And Marketing Expenses	Net Income From Continuing Ops	Non Operating Income Net Other	Tax Provision	Interest Income	Non Recurring	Net Interest Income	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		0.95	0.95	0.92	0.9	0.93	0.73	0.72	0.55	0.78	0.94	0.76	0.77	0.66	0.52	0.81	0.26	0.46	-0.83	0.8	0.4	-0.01	-0.89	0.93	0.72
Interest Expense	0.95		0.92	0.86	0.85	0.88	0.65	0.66	0.55	0.72	0.89	0.74	0.69	0.51	0.43	0.81	0.11	0.35	-0.79	0.8	0.4	0.03	-0.93	0.85	0.66
Selling General Administrative	0.95	0.92		0.96	0.96	0.97	0.81	0.8	0.7	0.85	0.95	0.87	0.83	0.48	0.6	0.78	0.2	0.56	-0.77	0.77	0.43	0.19	-0.89	0.8	0.62
Total Revenue	0.92	0.86	0.96		1.0	0.99	0.91	0.91	0.74	0.94	0.99	0.88	0.93	0.46	0.77	0.68	0.34	0.73	-0.72	0.66	0.33	0.33	-0.88	0.78	0.62
Gross Profit	0.9	0.85	0.96	1.0		0.99	0.92	0.91	0.76	0.94	0.98	0.89	0.93	0.43	0.77	0.67	0.32	0.73	-0.71	0.66	0.32	0.35	-0.87	0.76	0.6
Other Operating Expenses	0.93	0.88	0.97	0.99	0.99		0.86	0.85	0.79	0.89	0.98	0.9	0.87	0.44	0.7	0.68	0.33	0.66	-0.73	0.66	0.4	0.27	-0.88	0.78	0.61
Operating Income	0.73	0.65	0.81	0.91	0.92	0.86		1.0	0.6	0.99	0.88	0.76	1.0	0.35	0.93	0.51	0.31	0.9	-0.5	0.5	0.17	0.57	-0.71	0.6	0.47
Ebit	0.72	0.66	0.8	0.91	0.91	0.85	1.0		0.62	1.0	0.88	0.76	0.99	0.3	0.92	0.52	0.27	0.89	-0.49	0.5	0.17	0.61	-0.73	0.58	0.46
Research Development	0.55	0.55	0.7	0.74	0.76	0.79	0.6	0.62		0.63	0.69	0.89	0.58	-0.07	0.52	0.34	0.26	0.54	-0.36	0.32	0.43	0.41	-0.61	0.3	0.26
Ebitda	0.78	0.72	0.85	0.94	0.94	0.89	0.99	1.0	0.63		0.92	0.79	0.99	0.36	0.9	0.57	0.28	0.87	-0.55	0.56	0.2	0.55	-0.77	0.65	0.51
Cost Of Revenue	0.94	0.89	0.95	0.99	0.98	0.98	0.88	0.88	0.69	0.92		0.85	0.91	0.52	0.75	0.67	0.36	0.7	-0.73	0.66	0.34	0.26	-0.88	0.83	0.66
Total Operating Expenses	0.76	0.74	0.87	0.88	0.89	0.9	0.76	0.76	0.89	0.79	0.85		0.75	0.22	0.62	0.55	0.31	0.65	-0.6	0.53	0.44	0.29	-0.78	0.54	0.44
Income Before Tax	0.77	0.69	0.83	0.93	0.93	0.87	1.0	0.99	0.58	0.99	0.91	0.75		0.43	0.91	0.56	0.33	0.88	-0.56	0.54	0.17	0.51	-0.74	0.67	0.53
Total Other Income Expense Net	0.66	0.51	0.48	0.46	0.43	0.44	0.35	0.3	-0.07	0.36	0.52	0.22	0.43		0.26	0.51	0.46	0.18	-0.7	0.51	0.04	-0.47	-0.4	0.82	0.65
Net Income	0.52	0.43	0.6	0.77	0.77	0.7	0.93	0.92	0.52	0.9	0.75	0.62	0.91	0.26		0.17	0.51	0.98	-0.31	0.15	0.09	0.61	-0.49	0.42	0.33
Income Tax Expense	0.81	0.81	0.78	0.68	0.67	0.68	0.51	0.52	0.34	0.57	0.67	0.55	0.56	0.51	0.17		-0.22	0.11	-0.73	1.0	0.22	-0.03	-0.78	0.77	0.6
Selling And Marketing Expenses	0.26	0.11	0.2	0.34	0.32	0.33	0.31	0.27	0.26	0.28	0.36	0.31	0.33	0.46	0.51	-0.22		0.51	-0.38	-0.23	-0.17	-0.12	-0.18	0.35	0.33
Net Income From Continuing Ops	0.46	0.35	0.56	0.73	0.73	0.66	0.9	0.89	0.54	0.87	0.7	0.65	0.88	0.18	0.98	0.11	0.51		-0.26	0.09	0.09	0.63	-0.46	0.34	0.28
Non Operating Income Net Other	-0.83	-0.79	-0.77	-0.72	-0.71	-0.73	-0.5	-0.49	-0.36	-0.55	-0.73	-0.6	-0.56	-0.7	-0.31	-0.73	-0.38	-0.26		-0.72	0.02	0.27	0.85	-0.9	-0.64
Tax Provision	0.8	0.8	0.77	0.66	0.66	0.66	0.5	0.5	0.32	0.56	0.66	0.53	0.54	0.51	0.15	1.0	-0.23	0.09	-0.72		0.21	-0.04	-0.77	0.77	0.59
Interest Income	0.4	0.4	0.43	0.33	0.32	0.4	0.17	0.17	0.43	0.2	0.34	0.44	0.17	0.04	0.09	0.22	-0.17	0.09	0.02	0.21		-0.03	-0.15	0.12	0.05
Non Recurring	-0.01	0.03	0.19	0.33	0.35	0.27	0.57	0.61	0.41	0.55	0.26	0.29	0.51	-0.47	0.61	-0.03	-0.12	0.63	0.27	-0.04	-0.03		-0.15	-0.2	-0.16
Net Interest Income	-0.89	-0.93	-0.89	-0.88	-0.87	-0.88	-0.71	-0.73	-0.61	-0.77	-0.88	-0.78	-0.74	-0.4	-0.49	-0.78	-0.18	-0.46	0.85	-0.77	-0.15	-0.15		-0.82	-0.58
Reconciled Depreciation	0.93	0.85	0.8	0.78	0.76	0.78	0.6	0.58	0.3	0.65	0.83	0.54	0.67	0.82	0.42	0.77	0.35	0.34	-0.9	0.77	0.12	-0.2	-0.82		0.8
Extraordinary Items	0.72	0.66	0.62	0.62	0.6	0.61	0.47	0.46	0.26	0.51	0.66	0.44	0.53	0.65	0.33	0.6	0.33	0.28	-0.64	0.59	0.05	-0.16	-0.58	0.8

Click cells to compare fundamentals

Eagle Pharmaceuticals Account Relationship Matchups

Eagle Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	7.5M	4.8M	3.8M	12.0M	13.8M	14.5M
Interest Expense	2.7M	2.6M	1.6M	4.0M	4.7M	4.9M
Selling General Administrative	74.0M	75.9M	66.8M	98.1M	112.8M	118.5M
Total Revenue	195.9M	187.8M	171.5M	316.6M	364.1M	382.3M
Gross Profit	135.0M	142.3M	129.4M	221.7M	254.9M	267.7M
Other Operating Expenses	174.1M	154.8M	168.8M	235.7M	271.0M	284.5M
Operating Income	21.8M	25.3M	(2.9M)	53.5M	61.5M	64.5M
Ebit	21.8M	25.3M	(2.9M)	53.5M	61.5M	64.5M
Research Development	36.8M	30.8M	51.3M	34.1M	39.2M	32.8M
Ebitda	29.3M	30.0M	847K	65.5M	75.3M	79.1M
Cost Of Revenue	60.9M	45.5M	42.2M	94.9M	109.2M	114.6M
Total Operating Expenses	113.2M	109.4M	126.6M	140.7M	161.8M	89.0M
Income Before Tax	22.0M	22.7M	(4.5M)	61.4M	70.6M	74.2M
Total Other Income Expense Net	183K	(2.6M)	(1.6M)	8.0M	9.2M	9.6M
Net Income	14.3M	12.0M	(8.6M)	35.6M	41.0M	43.0M
Income Tax Expense	7.7M	10.7M	4.1M	25.8M	29.7M	31.1M
Selling And Marketing Expenses	3.3M	2.4M	2.7M	8.5M	9.8M	6.2M
Net Income From Continuing Ops	14.3M	12.0M	(8.6M)	35.6M	41.0M	24.8M
Non Operating Income Net Other	2.9M	(7.7M)	(5.7M)	(15.5M)	(13.9M)	(13.2M)
Net Income Applicable To Common Shares	14.3M	12.0M	(8.6M)	35.6M	41.0M	24.6M
Tax Provision	7.7M	10.7M	4.1M	25.8M	29.7M	31.1M
Interest Income	2.2M	562K	560K	271K	311.7K	537.5K
Non Recurring	13.0M	11.8M	10.7M	9.5M	8.5M	13.7M
Net Interest Income	(517K)	(2.0M)	(1.1M)	(3.8M)	(3.4M)	(3.2M)
Reconciled Depreciation	4.7M	4.8M	3.8M	12.0M	13.8M	14.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
CRM	Salesforce
MSFT	Microsoft

When determining whether Eagle Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eagle Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eagle Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eagle Pharmaceuticals Stock:

How To Invest In Eagle

Details

Is Eagle Stock a good investment?

Details

What is Eagle Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.

You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Complementary Tools for Eagle Stock analysis

When running Eagle Pharmaceuticals' price analysis, check to measure Eagle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eagle Pharmaceuticals is operating at the current time. Most of Eagle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eagle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eagle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eagle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules

Is Eagle Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eagle Pharmaceuticals. If investors know Eagle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eagle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.87)

Earnings Share

0.85

Revenue Per Share

19.684

Quarterly Revenue Growth

(0.13)

Return On Assets

0.0663

The market value of Eagle Pharmaceuticals is measured differently than its book value, which is the value of Eagle that is recorded on the company's balance sheet. Investors also form their own opinion of Eagle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eagle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eagle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eagle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Eagle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eagle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eagle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Eagle Historical Income Statement

About Eagle Income Statement Analysis

Eagle Pharmaceuticals Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Eagle Pharmaceuticals income statement Correlations

Eagle Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Eagle Pharmaceuticals income statement Accounts

Also Currently Popular

Complementary Tools for Eagle Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Ebit	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Tax Provision	+ 1.0	Income Tax Expense
Other Operating Expenses	+ 0.99	Total Revenue

Net Interest Income	- 0.93	Interest Expense
Reconciled Depreciation	- 0.9	Non Operating Income Net Other
Net Interest Income	- 0.89	Selling General Administrative
Net Interest Income	- 0.89	Depreciation And Amortization
Net Interest Income	- 0.88	Cost Of Revenue
Net Interest Income	- 0.88	Other Operating Expenses